NASDAQ:ANIPANI Pharmaceuticals Stock Price, Forecast & News

ANI Pharmaceuticals' stock was trading at $38.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ANIP stock has decreased by 19.3% and is now trading at $30.89. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ANI Pharmaceuticals.

ANI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for ANI Pharmaceuticals.

ANI Pharmaceuticals Inc (NASDAQ:ANIP) announced its quarterly earnings data on Thursday, May, 7th. The specialty pharmaceutical company reported $1.04 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $0.15. The specialty pharmaceutical company earned $49.77 million during the quarter, compared to analysts' expectations of $49.40 million. ANI Pharmaceuticals had a negative net margin of 0.67% and a positive return on equity of 23.92%. View ANI Pharmaceuticals' earnings history.

3 analysts have issued 12 month target prices for ANI Pharmaceuticals' shares. Their forecasts range from $40.00 to $58.00. On average, they expect ANI Pharmaceuticals' stock price to reach $49.00 in the next year. This suggests a possible upside of 58.6% from the stock's current price. View analysts' price targets for ANI Pharmaceuticals.

News coverage about ANIP stock has trended negative on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ANI Pharmaceuticals earned a news impact score of -2.2 on InfoTrie's scale. They also assigned news headlines about the specialty pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future. View the latest news about ANI Pharmaceuticals.

ANI Pharmaceuticals saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 559,500 shares, a decline of 10.1% from the June 15th total of 622,200 shares. Based on an average trading volume of 128,300 shares, the days-to-cover ratio is currently 4.4 days. Currently, 5.8% of the shares of the company are short sold. View ANI Pharmaceuticals' Current Options Chain.

Some companies that are related to ANI Pharmaceuticals include Mersana Therapeutics (MRSN), Cytokinetics (CYTK), MacroGenics (MGNX), Karyopharm Therapeutics (KPTI), Revance Therapeutics (RVNC), Akcea Therapeutics (AKCA), ZEALAND PHARMA/S (ZEAL), Innoviva (INVA), Portola Pharmaceuticals (PTLA), Kiniksa Pharmaceuticals (KNSA), Heron Therapeutics (HRTX), Esperion Therapeutics (ESPR), Amneal Pharmaceuticals (AMRX), Arvinas (ARVN) and Tricida (TCDA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Broadcom (AVGO), AbbVie (ABBV), Cisco Systems (CSCO), Intel (INTC) and NXP Semiconductors (NXPI).

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ANIP stock can currently be purchased for approximately $30.89.

ANI Pharmaceuticals has a market capitalization of $374.08 million and generates $206.55 million in revenue each year. The specialty pharmaceutical company earns $6.09 million in net income (profit) each year or $4.46 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.

The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]